Inovio Pharmaceuticals' Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models

BLUE BELL, Pa., Aug. 15, 2013 /PRNewswire via COMTEX/ -- Inovio Pharmaceuticals, Inc. announced today that its SynCon DNA vaccine containing multiple malaria antigens delivered via its CELLECTRA electroporation device demonstrated strong and durable antibody and T-cell immune responses in small animals and non-human primates.

http://it.tmcnet.com/news/2013/08/15/7345400.htm